NICE changes its mind on Janssen s Erleada pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
Janssen’s Erleada maintains quality of life for prostate cancer patients
27th May 2021
Janssen’s Erleada in addition to androgen deprivation therapy (ADT) maintained prostate cancer patients’ health-related quality of life (HRQoL), according to new patient-reported outcomes (PRO) data.
The PRO data from the prespecified final analysis of the Phase III TITAN study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) also showed that the addition of Erleada (apalutamide) to ADT did not worse side effect burden.
In both treatment groups – patients who received Erleada plus ADT and patients who received placebo plus ADT – HRQoL was maintained throughout the study.